Showing 4281-4290 of 5627 results for "".
- SyncThink Receives Second FDA Clearance for Mobile, Rapid Test for Concussionhttps://modernod.com/news/syncthink-receives-second-fda-clearance-for-first-mobile-rapid-test-for-concussion/2480327/SyncThink has received FDA clearance for its EYE-SYNC technology as an aid to concussion, or mild traumatic brain injury (mTBI) diagnosis. EYE-SYNC received breakthrough device designation from the FDA in 2019, following the initial clearance and commercialization of the technology plat
- Nidek Launches Retina Scan Duo 2 OCT/Fundus Camerahttps://modernod.com/news/nidek-launches-retina-scan-duotm-2-octfundus-camera/2480323/Nidek has announced the launch of the Retina Scan Duo 2, a combined OCT and fundus camera system. The Retina Scan Duo 2 incorporates new features designed to enhance screening and clinical efficiency, in addition to user-friendly features that were incorporated from the previous model.<
- Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Planhttps://modernod.com/news/orasis-pharmaceuticals-appoints-julie-speed-as-senior-vice-president-head-of-strategy-and-marketing-to-lead-commercial-growth-plan/2480321/Orasis Pharmaceuticals announced the appointment of Julie Speed as senior vice president (SVP), head of strategy and marketing. Ms. Speed brings over two decades of leadership in eye care and will be responsible for developing the brand strategy and building the marketin
- Adverum Presents Data Showing Gene Therapy Maintained Efficacy, Durability, Safety in Wet AMD Patientshttps://modernod.com/news/adverum-data-shows-gene-therapy-maintained-efficacy-durability-safety-in-wet-amd-patients/2480318/Adverum Biotechnologies announced new long-term data from the OPTIC clinical trial of ADVM-022 single, in-office intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). Safety and efficacy data f
- Ludwin Monz Stepping Down as CEO of Carl Zeiss Meditechttps://modernod.com/news/ludwin-monz-stepping-down-as-ceo-of-carl-zeiss-meditec/2480316/President and CEO of Carl Zeiss Meditec AG Ludwin Monz, PhD, announced that he will not be accepting another term in office, and will be stepping down from his postion effective December 31, 2021. The supervisory board has appointed Markus Weber, PhD, as the new President and
- Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trialhttps://modernod.com/news/outlook-therapeutics-reports-new-positive-12-month-safety-data-from-pivotal-phase-3-norse-two-trial/2480308/Outlook Therapeutics announced new 12-month safety data from the pivotal phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010/Lytenava (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). In August 2021, Outlook Ther
- Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Modelhttps://modernod.com/news/nicoxs-ncx-470-shows-retinal-cell-protection-in-a-nonclinical-model/2480307/Nicox reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1). NCX 470, Nicox’s lead clinical candidate, is a nitric oxide-donating prostaglandin analog currently in phase 3 clinical development for lowering IOP in patients with op
- Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medicalhttps://modernod.com/news/eyevensys-enters-collaboration-with-phillips-medisize-and-minnetronix-medical/2480302/Eyevensys has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology. Terms of the deal w
- US Eye Adds New Partnerships in Virginia, North Carolina, South Carolina, and Floridahttps://modernod.com/news/us-eye-adds-new-partnerships-in-virginia-north-carolina-south-carolina-and-florida/2480301/The US Eye practice network has recently expanded its practice base to 50 clinics and five surgery centers across the southeastern United States. Financial terms of the deal were not disclosed. US Eye has partnered with Griffey Eye Care located in Chesapeake, Virginia; Al
- RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditionshttps://modernod.com/news/rd-fund-launches-opus-genetics-with-19m-seed-funding-to-advance-gene-therapy-treatments-for-blinding-conditions/2480298/The Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness, announced the launch of